Divi's Laboratories Limited : Press Release Qtr 4 2012-13.

DIVI'S LABORATORIES LIMITED Divi Towers, Dharam Karan Road Hyderabad 500 016

Phone: [phone] email: [e-mail]

PRESS RELEASE dated 20TH May, 2013

Divi's Labs earns a consolidated Total Income of

Rs.2145 crores in FY13.

Consolidated for the year

Divi's Laboratories has earned a consolidated total income of Rs.2145 crores for the financial year 2012-13 as against a total income of Rs.1864 crores during the last year, reflecting a growth of 15%.
PBT for the current year came to Rs. 781 crores as against a
PBT of Rs.681 crores for the previous year.
Tax for the year is provided at Rs.179 crores as against a tax provision of Rs.147 crores for the previous year.
PAT for the year is Rs. 602 crores as against a PAT of Rs.533 crores for the last year.

Consolidated for the 4th quarter

For the current quarter of the year, the company earned a PAT
of Rs.181 crores on a total income of Rs.658 crores.

Standalone

On a standalone basis, the company's earnings are as given below:

Particulars	For the Quarter	For the year
	Current	Previous	Current	Previous
Total Income	651	711	2129	1845

PBT	239	271	792	695
PAT	182	215	611	546

Operations

The Board has declared a dividend of Rs.15 per share i.e.,
750% subject to approval of members.
Due to the continuing severe power shortage in the State of Andhra Pradesh, the company had to rely on purchased power at higher cost.
Particulars of forex gain/(loss) for the period are given below:

	Standalone		Consolidated
	Quarter ended 31-03-13	Year Ended 31-03-13		Quarter ended 31-03-13	Year Ended 31-03-13
Forex gain/(loss)	(975.10)	1516.40		(777.78)	1145.21

While forex gain has been included in Other Income, forex loss has been included in Other Expenses.
Exports constituted 90% of sales and about 76% to advanced markets in North America and Europe.
During the year, addition to Fixed Assets amounted to Rs.248 crores. In addition, an amount of Rs.303 crores is carried forward as Capital WIP for the Capital Works under execution.
During the year Unit-II facility was successfully inspected by TGA, Australia (GMP), USFDA for Nutraceutical facility, USFDA for API site (pre-approval and cGMP), Slovenian Medicines Agency (EU GMP inspection for 7 APIs).